Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 3/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | GRK2 | P25098 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18773998 | 0.83 | MEN1 (0.61) | MMP13KMT2AMEN1NAMPTROCK2 | |
| SCHEMBL13211819 | 0.82 | MMP13 (0.84) | MMP13KMT2AMEN1NAMPTPOLB | |
| SCHEMBL12678010 | 0.79 | HCAR2 (0.55) | KMT2AMEN1NAMPTHCAR2ATM | |
| SCHEMBL11187328 | 0.77 | KMT2A (0.66) | MMP13KMT2AMEN1NAMPTROCK2 | |
| SCHEMBL17297343 | 0.76 | HCAR2 (0.51) | KMT2AMEN1HCAR2ATM | |
| SCHEMBL12459627 | 0.75 | MMP13 (0.57) | MMP13KMT2AMEN1NAMPTGAA | |
| SCHEMBL17297327 | 0.75 | HCAR2 (0.50) | KMT2AMEN1HCAR2ATM | |
| SCHEMBL12048998 | 0.74 | HCAR2 (0.62) | KMT2AMEN1HCAR2ATM | |
| SCHEMBL14625555 | 0.74 | MMP13 (0.53) | MMP13KMT2AMEN1NAMPTROCK2 | |
| SCHEMBL30633434 | 0.73 | MEN1 (0.60) | MMP13KMT2AMEN1NAMPTROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230155-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2025-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230155-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | CHRM5, CHRM4, CHRM1 | MMP13 4685/4885KMT2A 832/4885MEN1 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.